Colonic Delivery of Vasoactive Intestinal Peptide Nanomedicine Alleviates Colitis and Shows Promise as An Oral Capsule

References

• Abad C , WaschekJA. Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis. Curr. Pharm. Des.17(10), 1025–1035 (2011).
   PubMed Web of Science ®Google Scholar
• Delgado M , MartinezC, PozoDet al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J. Immunol.162(2), 1200–1205 (1999).
   PubMed Web of Science ®Google Scholar
• Gomariz R , MartinezC, AbadC, LecetaJ, DelgadoM. Immunology of VIP: a review and therapeutical perspectives. Curr. Pharm. Des.7(2), 89–111 (2001).
   PubMed Web of Science ®Google Scholar
• Smalley S , BarrowP, FosterN. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin. Exp. Immunol.157(2), 225–234 (2009).
   PubMed Web of Science ®Google Scholar
• Seo S , MiyakeH, AlganabiMet al. Vasoactive intestinal peptide decreases inflammation and tight junction disruption in experimental necrotizing enterocolitis. J. Pediatr. Surg.54(12), 2520–2523 (2019).
   PubMed Web of Science ®Google Scholar
• Campbell J , BerryJ, LiangY. Anatomy and physiology of the small intestine. In: Shackelford’s Surgery of the Alimentary Tract - 2 Volume Set.Elsevier, PA, USA, 817–841 (2019).
   Google Scholar
• Seillet C , LuongK, TellierJet al. The neuropeptide VIP confers anticipatory mucosal immunity by regulating ILC3 activity. Nat. Immunol.21, 168–177 (2019).
   PubMed Web of Science ®Google Scholar
• Jönsson M , NorrgårdÖ, HanssonM, ForsgrenS. Decrease in binding for the neuropeptide VIP in response to marked inflammation of the mucosa in ulcerative colitis. Ann. NY Acad. Sci.1107(1), 280–289 (2007).
   PubMedGoogle Scholar
• Mazumdar S , DasKM. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am. J. Gastroenterol.87(2), 176–181 (1992).
   PubMed Web of Science ®Google Scholar
• Cassuto J , FahrenkrugJ, JodalM, TuttleR, LundgrenO. Release of vasoactive intestinal polypeptide from the cat small intestine exposed to cholera toxin. Gut22(11), 958–963 (1981).
   PubMed Web of Science ®Google Scholar
• Guan X , KarpenHE, StephensJet al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology130(1), 150–164 (2006).
   PubMed Web of Science ®Google Scholar
• Dharmsathaphorn K , HarmsV, YamashiroDJ, HughesR, BinderH, WrightE. Preferential binding of vasoactive intestinal polypeptide to basolateral membrane of rat and rabbit enterocytes. J. Clin. Invest.71(1), 27–35 (1983).
   PubMed Web of Science ®Google Scholar
• Jayawardena D , GuzmanG, GillRK, AlrefaiWA, OnyukselH, DudejaPK. Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine. Am. J. Physiol. Gastrointest. Liver Physiol.313(1), G16–G25 (2017).
   PubMed Web of Science ®Google Scholar
• Jayawardena D , AnbazhaganAN, GuzmanG, DudejaPK, OnyukselH. Vasoactive intestinal peptide nanomedicine for the management of inflammatory bowel disease. Mol. Pharm.14(11), 3698–3708 (2017).
   PubMedGoogle Scholar
• Abad C , MartinezC, JuarranzMGet al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease. Gastroenterology124(4), 961–971 (2003).
   PubMed Web of Science ®Google Scholar
• Motlekar NA , YouanB-BC. The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins. J. Control. Rel.113(2), 91–101 (2006).
   PubMed Web of Science ®Google Scholar
• Lim SB , RubinsteinI, ÖnyükselH. Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles. Int. J. Pharm.356(1–2), 345–350 (2008).
   PubMed Web of Science ®Google Scholar
• Nair AB , JacobS. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm.7(2), 27 (2016).
   PubMedGoogle Scholar
• Sethi V , RubinsteinI, KuzmisA, KastrissiosH, ArtwohlJ, OnyukselH. Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis. Mol. Pharm.10(2), 728–738 (2013).
   PubMedGoogle Scholar
• Banerjee A , OnyukselH. Peptide delivery using phospholipid micelles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.4(5), 562–574 (2012).
   PubMed Web of Science ®Google Scholar
• Lim SB , BanerjeeA, ÖnyükselH. Improvement of drug safety by the use of lipid-based nanocarriers. J. Control. Rel.163(1), 34–45 (2012).
   PubMed Web of Science ®Google Scholar
• Vukovic L , MadriagaA, KuzmisAet al. Solubilization of therapeutic agents in micellar nanomedicines. Langmuir29(51), 15747–15754 (2013).
   PubMed Web of Science ®Google Scholar
• Krawisz J , SharonP, StensonW. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity: assessment of inflammation in rat and hamster models. Gastroenterology87(6), 1344–1350 (1984).
   PubMed Web of Science ®Google Scholar
• Viennois E , ChenF, LarouiH, BakerMT, MerlinD. Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: lithium chloride purification, a rapid and efficient technique to purify RNA. BMC Res. Notes6(1), 360 (2013).
   PubMedGoogle Scholar
• Schmittgen TD , LivakKJ. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc.3(6), 1101–1108 (2008).
   PubMed Web of Science ®Google Scholar
• Lindén SK , FlorinTH, McguckinMA. Mucin dynamics in intestinal bacterial infection. PLoS ONE3(12), e3952 (2008).
   PubMed Web of Science ®Google Scholar
• McConnell EL , FaddaHM, BasitAW. Gut instincts: explorations in intestinal physiology and drug delivery. Int. J. Pharm.364(2), 213–226 (2008).
   PubMed Web of Science ®Google Scholar
• Önyüksel H , BodaliaB, SethiV, DagarS, RubinsteinaI. Surface-active properties of vasoactive intestinal peptide*. Peptides21(3), 419–423 (2000).
   PubMed Web of Science ®Google Scholar
• Kaplan GG . The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol.12(12), 720–727 (2015).
   PubMed Web of Science ®Google Scholar
• Frokjaer S , OtzenDE. Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov.4(4), 298 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis AL , RichardJ. Challenges in the delivery of peptide drugs: an industry perspective. Ther. Deliv.6(2), 149–163 (2015).
   PubMedGoogle Scholar
• Richard J . Challenges in oral peptide delivery: lessons learnt from the clinic and future prospects. Ther. Deliv.8(8), 663–684 (2017).
   PubMed Web of Science ®Google Scholar
• Sarmento B , RibeiroA, VeigaF, SampaioP, NeufeldR, FerreiraD. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res.24(12), 2198–2206 (2007).
   PubMed Web of Science ®Google Scholar
• Sarmento B , MartinsS, FerreiraD, SoutoEB. Oral insulin delivery by means of solid lipid nanoparticles. Int. J. Nanomedicine2(4), 743 (2007).
   PubMed Web of Science ®Google Scholar
• Araújo F , ShresthaN, ShahbaziM-Aet al. The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. Biomaterials35(33), 9199–9207 (2014).
   PubMed Web of Science ®Google Scholar
• Li C , ZhaoY, ChengJet al. A proresolving peptide nanotherapy for site-specific treatment of inflammatory bowel disease by regulating proinflammatory microenvironment and gut microbiota. Adv. Sci.6(18), 1900610 (2019).
   Web of Science ®Google Scholar
• Laroui H , DalmassoG, NguyenHTT, YanY, SitaramanSV, MerlinD. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology138(3), 843–853 (2010).
   PubMed Web of Science ®Google Scholar
• Ensign LM , ConeR, HanesJ. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev.64(6), 557–570 (2012).
   PubMed Web of Science ®Google Scholar
• Des Rieux A , FievezV, GarinotM, SchneiderY-J, PréatV. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Rel.116(1), 1–27 (2006).
   PubMed Web of Science ®Google Scholar
• Hamman JH , EnslinGM, KotzéAF. Oral delivery of peptide drugs. BioDrugs19(3), 165–177 (2005).
   PubMed Web of Science ®Google Scholar
• Hua S , MarksE, SchneiderJJ, KeelyS. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine11(5), 1117–1132 (2015).
   PubMed Web of Science ®Google Scholar
• Xiao B , MerlinD. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert Opin. Drug Deliv.9(11), 1393–1407 (2012).
   PubMed Web of Science ®Google Scholar
• Taipaleenmäki EM , MouritzenSA, SchattlingPS, ZhangY, StädlerB. Mucopenetrating micelles with a PEG corona. Nanoscale9(46), 18438–18448 (2017).
   PubMed Web of Science ®Google Scholar
• Chapman NJ , BrownML, PhillipsSFet al. Distribution of mesalamine enemas in patients with active distal ulcerative colitis. Mayo Clin. Proc.67(3), 245–248 (1992).
   PubMed Web of Science ®Google Scholar
• Sandborn W , TremaineW, LeightonJAet al. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment. Pharmacol. Ther.11(4), 663–671 (1997).
   PubMed Web of Science ®Google Scholar
• Greenfield NJ . Using circular dichroism spectra to estimate protein secondary structure. Nat. Protoc.1(6), 2876 (2006).
   PubMed Web of Science ®Google Scholar
• Mody R , TramontanoA, PaulS. Spontaneous hydrolysis of vasoactive intestinal peptide in neutral aqueous solution. Chem. Biol. Drug Des.44(5), 441–447 (1994).
   Google Scholar
• Cui X , CaoD, QuC, ZhangX, ZhengA. A study of the chemical and biological stability of vasoactive intestinal peptide. Drug Dev. Ind. Pharm.39(12), 1907–1910 (2013).
   PubMed Web of Science ®Google Scholar